The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000951358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
30/06/2026
Date registered
Help: Date registered
3/08/2026
Date last updated
Help: Date last updated
3/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
3/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Proof-of-concept Single-arm clinical trial Of semaglutide after withdrawal of biologic therapy for chronic plaque psoriasis in people with overweight/obesity (PSO-withdraw)
Scientific title
A Proof-of-concept Single-arm clinical trial Of semaglutide after withdrawal of biologic therapy for control of chronic plaque psoriasis in people with overweight/obesity (PSO-withdraw)
Additional trial identifiers [1] 317739 0
Nil known
Universal Trial Number (UTN)
Trial acronym
PSO-Withdraw
Related trial records

Health condition
Health condition(s) studied:
psoriasis 342640 0
obesity 342641 0
chronic plaque psoriasis 342642 0
Condition category
Condition code
Diet and Nutrition 338782 338782 0 0
Obesity
Skin 338783 338783 0 0
Dermatological conditions
Inflammatory and Immune System 338784 338784 0 0
Autoimmune diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
In this study, semaglutide will be given upon stopping biologic therapy to see if it helps maintain psoriasis control. Participants who are currently on a biologic for their Chronic Plaque Psoriasis (CPP) will cease their biologic and commence the semaglutide. Some examples of biologics commonly used for CPP are guselkumab and risankizumab. Other Pharmaceutical Benefit Scheme (PBS) approved biologics for CPP are adalimumab, bimekizumab, etanercept, infliximab, ixekizumab, secukinumab, tildrakizumab and ustekinumab.

The investigational product (IP) in this study is semaglutide is a once-weekly subcutaneous injection approved for type 2 diabetes and weight management. Once enrolled, participants will be trained by a nurse to self-inject the semaglutide and will self-inejct all subsequent doses.

Participants will be titrated up on the semaglutide. They will initially be dosed at 0.25mg and escalate according to standard dosing schedule to a target of 2.4 mg weekly over 16 weeks. Participant will be seen monthly during dose escalation and approximately every 8-10 weeks during the maintenance phase. The maintenance phase will last from Week 24 - Week 52.

If dose escalation leads to unacceptable adverse effects, dose-escalation intervals will be extended or the maximum tolerated dose used for the remainder of the 52-week study.

Adherence to intervention will be monitored by measuring weight and health outcomes. In addition, participants will be asked to return empty kits for IP accountability.
Intervention code [1] 334579 0
Treatment: Drugs
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345979 0
To determine whether initiation of semaglutide at the time of biologic therapy discontinuation maintains psoriasis disease control in adults with chronic plaque psoriasis and overweight/obesity.
Timepoint [1] 345979 0
12 months post discontinuation of biologic therapy and initiation of semaglutide
Secondary outcome [1] 463996 0
To evaluate the effects of semaglutide on body weight
Timepoint [1] 463996 0
12 months post discontinuation of biologic therapy and initiation of semaglutide. Body weight will be assessed at the following timepoints: Screening, Baseline, Week(W) 12, W24, W32, W42 and W52
Secondary outcome [2] 464702 0
To evaluate the effects of semaglutide on metabolic health
Timepoint [2] 464702 0
12 months post discontinuation of biologic therapy and initiation of semaglutide Blood pressure will be collected throughout the trial Blood collection will be at Baseline, Week 24 and Week 52
Secondary outcome [3] 464703 0
To evaluate the effects of semaglutide on Quality of Life (QoL)
Timepoint [3] 464703 0
12 months post discontinuation of biologic therapy and initiation of semaglutide QoL questionnaires will be completed by participants at Baseline, Week 24 and Week 52
Secondary outcome [4] 464704 0
Safety of semaglutide in participants enrolled on trial. (Participants with Chronic plaque psoriasis (CPP) who are overweight/obese)
Timepoint [4] 464704 0
12 months post discontinuation of biologic therapy and initiation of semaglutide
Secondary outcome [5] 465238 0
Inflammatory and Molecular Markers This will be assessed as a composite outcome. Biomarkers/changes assessed will be an exploratory outcome.
Timepoint [5] 465238 0
At Baseline visit and one repeat between Weeks 8-16
Secondary outcome [6] 465239 0
To evaluate the effects of semaglutide on waist circumference
Timepoint [6] 465239 0
At Baseline, Week(W) 12, W24, W32, W42 and W52

Eligibility
Key inclusion criteria
Adults aged 18–75 years with chronic plaque psoriasis.

Overweight or obesity (BMI greater than or equal to 27 kg/m²).

On biologic therapy for at least 6 months with complete or near-complete response (PASI 90 or 100).

Able to provide informed consent and discontinue biologic therapy at baseline.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Other forms of psoriasis (e.g. pustular, guttate).

Contraindication or intolerance to GLP-1 receptor agonist therapy.

Recent use of GLP-1 receptor agonists or other obesity medications.

Severe comorbidities (e.g., recent cardiovascular event, severe renal impairment, active infection).

Pregnancy, breastfeeding, or planned pregnancy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
Descriptive statistics will be used to summarise participant characteristics and study outcomes. As this is a proof-of-concept, exploratory study, formal hypothesis testing and significance testing will not be performed.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29736 0
The Alfred - Melbourne
Recruitment postcode(s) [1] 46083 0
3004 - Melbourne

Funding & Sponsors
Funding source category [1] 322281 0
Hospital
Name [1] 322281 0
The Alfred
Country [1] 322281 0
Australia
Primary sponsor type
Hospital
Name
Bayside Health
Address
Country
Australia
Secondary sponsor category [1] 325198 0
None
Name [1] 325198 0
Address [1] 325198 0
Country [1] 325198 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320797 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 320797 0
Ethics committee country [1] 320797 0
Australia
Date submitted for ethics approval [1] 320797 0
23/02/2026
Approval date [1] 320797 0
17/06/2026
Ethics approval number [1] 320797 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151662 0
Prof Johannes Kern
Address 151662 0
The Alfred Hospital, 55 Commercial Road, Melbourne, VIC, 3004
Country 151662 0
Australia
Phone 151662 0
+61 3 9076 8592
Fax 151662 0
Email 151662 0
Contact person for public queries
Name 151663 0
Frances Burns
Address 151663 0
The Alfred Hospital, 55 Commercial Road, Melbourne, VIC, 3004
Country 151663 0
Australia
Phone 151663 0
+61 3 9076 8592
Fax 151663 0
Email 151663 0
Contact person for scientific queries
Name 151664 0
Johannes Kern
Address 151664 0
The Alfred Hospital, 55 Commercial Road, Melbourne, VIC, 3004
Country 151664 0
Australia
Phone 151664 0
+61 3 9076 8592
Fax 151664 0
Email 151664 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.